CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of hepatobiliary cancers.
  
  LEARNING OBJECTIVES

  • Consider patient age, performance status, liver function and other clinical and logistical factors in the selection of first- and later-line therapy for unresectable or metastatic hepatocellular carcinoma (HCC).
  • Consider the FDA approval of olaparib as maintenance therapy for patients with metastatic pancreatic adenocarcinoma (PAD) with deleterious or suspected deleterious germline BRCA mutations and without disease progression on a first-line platinum-based chemotherapy regimen.
  • Apply clinical trial data with approved and investigational systemic interventions for patients with localized, locally advanced or metastatic PAD to establish an evidence-based approach to selecting therapy.
  • Appraise available and emerging data with investigational agents currently in clinical testing for HCC, PAD, and biliary tract cancers, and appropriately refer eligible patients for clinical trial participation.
  • Evaluate the data with approved and investigational agents targeting FGFR2 fusions or rearrangements in patients with cholangiocarcinoma, and identify individuals who would benefit from this strategy.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY & MODERATOR — The following faculty and moderator reported relevant financial relationships with ineligible entities:
  
  FACULTY
  
  Ghassan Abou-Alfa, MD, MBA
  Professor
  Attending Physician
  Memorial Sloan Kettering Cancer Center
  New York, New York
  
  Consulting Agreements: Adicet Bio, Alnylam Pharmaceuticals Inc, AstraZeneca Pharmaceuticals LP, Autem Medical, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Berry Genomics, Celgene Corporation, Cend Therapeutics Inc, CytomX Therapeutics, Eisai Inc, Exelixis Inc, Flatiron Health, Genentech, a member of the Roche Group, Genoscience Pharma, Helio Health, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Legend Biotech, Lilly, Merck, Nerviano Medical Sciences Srl, QED Therapeutics, Rafael Pharmaceuticals Inc, RedHill Biopharma Ltd, Servier Pharmaceuticals LLC, Silenseed Ltd, Sobi, Surface Oncology, TheraBionic, Vector Pharma, Yiviva; Contracted Research: Agios Pharmaceuticals Inc, Arcus Biosciences, AstraZeneca Pharmaceuticals LP, BioNTech, Bristol-Myers Squibb Company, Celgene Corporation, Flatiron Health, Genentech, a member of the Roche Group, Genoscience Pharma, Incyte Corporation, Polaris Pharmaceuticals, Puma Biotechnology Inc, QED Therapeutics, Silenseed Ltd, Yiviva.
  
  Richard S Finn, MD
  Professor, Department of Medicine, Division of Hematology/Oncology
  David Geffen School of Medicine at UCLA
  Director, Signal Transduction and Therapeutics Program
  Jonsson Comprehensive Cancer Center at UCLA
  Los Angeles, California
  
  Advisory Committee: CStone Pharmaceuticals; Consulting Agreements: Adaptimmune, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, CStone Pharmaceuticals, Eisai Inc, Exelixis Inc, Genentech, a member of the Roche Group, Lilly, Merck, Pfizer Inc; Contracted Research (to UCLA): Adaptimmune, Bayer HealthCare Pharmaceuticals, Eisai Inc, Genentech, a member of the Roche Group, Lilly, Merck, Pfizer Inc; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP, Hengrui Therapeutics Inc.
  
  Robin K (Katie) Kelley, MD
  Associate Professor of Clinical Medicine
  Helen Diller Family Comprehensive Cancer Center
  University of California, San Francisco (UCSF)
  San Francisco, California
  
  Advisory Committee: Agios Pharmaceuticals Inc, AstraZeneca Pharmaceuticals LP, Ipsen Biopharmaceuticals Inc, Merck; Consulting Agreement: Exact Sciences Inc; Contracted Research: Agios Pharmaceuticals Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, EMD Serono Inc, Exelixis Inc, Genentech, a member of the Roche Group, Lilly, Merck, Novartis, Partner Therapeutics, QED Therapeutics, Surface Oncology, Taiho Oncology Inc; Data and Safety Monitoring Board/Committee: Genentech, a member of the Roche Group, Merck.
  
  MODERATOR
  
  Tanios Bekaii-Saab, MD
  Professor, Mayo Clinic College of Medicine and Science
  Program Leader, Gastrointestinal Cancer
  Mayo Clinic Cancer Center
  Consultant, Mayo Clinic in Arizona
  Chair, ACCRU Research Consortium
  Phoenix, Arizona
  
  Advisory Committee: Immuneering Corporation, Imugene, Sun Biopharma; Consulting Agreements (to Institution): Arcus Biosciences, Array BioPharma Inc, a subsidiary of Pfizer Inc, Bayer HealthCare Pharmaceuticals, Genentech, a member of the Roche Group, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Merck, Pfizer Inc, Seagen Inc; Consulting Agreements (to Self): AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Boehringer Ingelheim Pharmaceuticals Inc, Celularity, Daiichi Sankyo Inc, Eisai Inc, Exact Sciences, Foundation Medicine, Janssen Biotech Inc, Kanaph Therapeutics, Natera Inc, Sobi, Stemline Therapeutics Inc, Treos Bio, Xilis; Research Funding (to Institution): AbGenomics, Agios Pharmaceuticals Inc, Amgen Inc, Arcus Biosciences, Arrys Therapeutics, a wholly owned subsidiary of Kyn Therapeutics, Atreca, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Genentech, a member of the Roche Group, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Lilly, Merck, Merus BV, Mirati Therapeutics, Novartis, Pfizer Inc, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc; Data and Safety Monitoring Board/Committee: 1Globe Health Institute, AstraZeneca Pharmaceuticals LP, Exelixis Inc, FibroGen, Kintor, Lilly, Pancreatic Cancer Action Network; Inventions/Patents: WO/2018/183488, WO/2019/055687.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Exelixis Inc, Genentech, a member of the Roche Group, Incyte Corporation and Zymeworks Inc.
  
  Release date: February 2022
  Expiration date: February 2023